Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896300 | 0.80 | KCNH2 (0.62) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL21588444 | 0.80 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL9963514 | 0.77 | RAB9A (0.74) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL21981950 | 0.74 | HRH3 (0.47) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL21981682 | 0.73 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL20101049 | 0.72 | SMN1; SMN2 (0.59) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL24330005 | 0.71 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL24359019 | 0.71 | SMN1; SMN2 (0.66) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL21114767 | 0.70 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL1656708 | 0.70 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-10-19 | — | — | US | disclosed |
| EP-4252853-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Oncology Limited (IN) | 2023-10-04 | — | — | EP | disclosed |
| EP-3600270-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE ONCOLOGY LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-10640517-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640517-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | RAB9A 3927/4885SMN1; SMN2 1090/4885NPC1 1258/4885 |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | RAB9A 4067/4885SMN1; SMN2 1309/4885NPC1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.